Epigenetic modulation of AREL1 and increased HLA expression in brains of multiple system atrophy patients

Multiple system atrophy (MSA) is a rare disease with a fatal outcome. To date, little is known about the molecular processes underlying disease development. Its clinical overlap with related neurodegenerative movement disorders underlines the importance for expanding the knowledge of pathological br...

Full description

Saved in:
Bibliographic Details
Published in:Acta neuropathologica communications 2020-03, Vol.8 (1), p.29-29, Article 29
Main Authors: Rydbirk, Rasmus, Folke, Jonas, Busato, Florence, Roché, Elodie, Chauhan, Alisha Shahzad, Løkkegaard, Annemette, Hejl, Anne-Mette, Bode, Matthias, Blaabjerg, Morten, Møller, Mette, Danielsen, Erik Hvid, Brudek, Tomasz, Pakkenberg, Bente, Tost, Jorg, Aznar, Susana
Format: Article
Language:English
Subjects:
5-Methylcytosine - analogs & derivatives
Age
Aged
Aged, 80 and over
Antigens
Biochemistry, Molecular Biology
Brain
Case-Control Studies
Deoxyribonucleic acid
Development and progression
Disease
Diseases
DNA
DNA Methylation
Epigenesis, Genetic
Epigenetic inheritance
Epigenetics
Epigenome
EWAS
Female
Flow Cytometry
Gene expression
Genes
Genetics
Genomes
Genomics
HLA antigens
HLA Antigens - genetics
HLA Antigens - immunology
Humans
Hydroxymethylation
Immune system
Internet resources
Killer cells
Killer Cells, Natural - immunology
Leukocytes, Mononuclear - immunology
Life Sciences
Male
Medical research
Methylation
Middle Aged
Monocytes - immunology
Multiple system atrophy
Multiple System Atrophy - genetics
Multiple System Atrophy - immunology
Neuroinflammation
Patients
Prefrontal Cortex - metabolism
Pyrimidines
Rare diseases
Studies
T-Lymphocytes - immunology
Transcriptome
Ubiquitin-Protein Ligases - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple system atrophy (MSA) is a rare disease with a fatal outcome. To date, little is known about the molecular processes underlying disease development. Its clinical overlap with related neurodegenerative movement disorders underlines the importance for expanding the knowledge of pathological brain processes in MSA patients to improve distinction from similar diseases. In the current study, we investigated DNA methylation changes in brain samples from 41 MSA patients and 37 healthy controls. We focused on the prefrontal cortex, a moderately affected area in MSA. Using Illumina MethylationEPIC arrays, we investigated 5-methylcytosine (5mC) as well as 5-hydroxymethylcytosine (5hmC) changes throughout the genome. We identified five significantly different 5mC probes (adj. P 
ISSN:2051-5960
2051-5960
DOI:10.1186/s40478-020-00908-7